文献速递胸部介入CT

胸外科团队对476例连续患者肺部肿瘤行CT引导射频消融的长期观察:单中心经验

Long-term Observation of CT-guided Radiofrequency Ablation of Lung Neoplasm in 476 Consecutive Patients by a Thoracic Surgical Service: A Single-institutional Experience.
PubMed 文献 · Acad Radiol · 2017-09-06

研究回顾性分析2004年9月至2016年3月单中心476例医学上无法手术的肺部肿瘤患者(668个病灶)行CT引导射频消融的长期生存与局部控制。原发性非小细胞肺癌1、2、3、5、10年总生存率分别为98.1%、86.6%、68.9%、34.5%、9.5%。

要点

  • 主要并发症为低级别发热(21.8%)和气胸(9.6%)。
  • 原发性非小细胞肺癌10年总生存率为9.5%,转移性肿瘤10年总生存率为1.5%。

核心结论

  • 胸外科医生实施的CT引导射频消融在高风险患者中可行且安全;最大肿瘤直径小于3 cm和无肺外转移是射频消融后生存的有利预后因素;射频消融对复发性非小细胞肺癌、肺转移和小细胞肺癌也提供良好的长期局部控制;射频消融应继续作为医学上无法手术患者的替代选择。

研究设计与样本

  • 单中心长期观察性研究,纳入2004年9月至2016年3月476例医学上无法手术的肺部肿瘤患者(294例男性,60例女性;中位年龄74岁,范围29-84岁),共治疗668个肿瘤;所有患者均有肿瘤性病变的临床或病理证据;病灶平均大小3.8 cm(范围1-16 cm);21个病灶接受1至4次重复治疗。

诊断标准与关键数值

  • 原发性非小细胞肺癌1、2、3、5、10年总生存率分别为98.1%、86.6%、68.9%、34.5%、9.5%。
  • 转移性肿瘤1、2、3、5、10年总生存率分别为59.7%、18.5%、8%、3.4%、1.5%。
  • 复发性非小细胞肺癌1、2、3、5、10年总生存率分别为93.3%、59.1%、49.6%、19.7%、0%。
  • 小细胞肺癌1、2、3、5、10年总生存率分别为89.4%、67.5%、39.1%、16.5%、0%。
  • 原发性非小细胞肺癌中,无进展生存和总生存与肿瘤大小显著相关;复发性非小细胞肺癌、转移和小细胞肺癌中无显著差异。

临床应用与阅片要点

  • 原发性非小细胞肺癌直径小于3 cm者1年随访影像任何类型复发率为7.1%。
  • 非小细胞肺癌转移患者的中位总生存与淋巴结或远处转移显著相关。
  • 射频消融应继续作为医学上无法手术患者的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: The aim of the study was to evaluate the overall survival (OS) rate, progression survival rate, and local control rate over 10 years of medically inoperable patients with lung cancer undergoing computed tomography (CT)-guided radiofrequency ablation (RFA).

MATERIALS AND METHODS: Between September 2004 to March 2016, 668 neoplasms were treated in 476 medically inoperable patients (294 men, 60 women; median age 74 years; range 29-84) who underwent CT-guided RFA. All patients had clinical or pathologic evidence of the neoplastic lesion: 22.1% patients with primary non-small cell lung cancer (NSCLC), 22.3% patients with recurrent NSCLC, 45.2% with metastases, and 10.3% with small cell lung cancer. The mean size of the lesions was 3.8 cm (range of 1-16 cm). Twenty-one lesions were re-treated from one to as many as four times.

RESULTS: The procedure was technically successful in all cases. No procedure-related deaths occurred in the RFA procedures. Major complications consisted in 104 (21.8%) cases of low-grade fever, 46 (9.6%) of the pneumothorax. The mean follow-up was 32 months. The probabilities of 1-, 2-, 3-, 5-, and 10-year OS rate were 98.1%, 86.6%, 68.9% 34.5%, and 9.5% for primary NSCLC; 59.7%, 18.5%, 8%, 3.4%, and 1.5% for metastases; 93.3%, 59.1%, 49.6%, 19.7%, and 0% for recurrence; and 89.4%, 67.5%, 39.1%, 16.5%, and 0% for small cell lung cancer. In primary NSCLC, progression-free survival (PFS) and OS were significantly related to tumor size, but there was no significant difference in recurrent NSCLC, metastasis, and peripheral SCLC. The median OS of metastases of NSCLC was significantly related to nodal or distant metastases. The most common pattern of recurrence was local; any type of recurrence at 1-year follow-up imaging was seen in 7.1% of primary NSCLC diameter less than 3 cm.

CONCLUSIONS: Our experience indicates that CT-guided RFA done by the thoracic surgeons is feasible and safe in high-risk patients. Maximum tumor diameter less than 3 cm and lack of extrapulmonary metastasis are all positive prognostic factors of survival after RFA. RFA offers good local control of recurrent NSCLC, lung metastases, and SCLC, also in the long-term period. RFA should continue to offer an alternative option in medically inoperable patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Huang BY, Zhou JJ, Yu ZQ, et al. Long-term Observation of CT-guided Radiofrequency Ablation of Lung Neoplasm in 476 Consecutive Patients by a Thoracic Surgical Service: A Single-institutional Experience. Acad Radiol. 2017. PMID: 28888381. doi:10.1016/j.acra.2017.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。